Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb;80(3):335-339.
doi: 10.1007/s40265-020-01269-0.

Givosiran: First Approval

Lesley J Scott  1
Affiliations
Review

Givosiran: First Approval

Lesley J Scott. Drugs. 2020 Feb.

Abstract

Givosiran (Givlaari™) is an aminolevulinate synthase 1 (ALAS1)-directed small interfering RNA (siRNA) covalently linked to a ligand to enable specific delivery of the siRNA to hepatocytes. This results in downregulation of ALAS1 mRNA and prevents accumulation of neurotoxic δ-aminolevulinic acid and porphobilinogen levels that are associated with acute porphyria attacks. Givosiran is being developed by Alnylam Pharmaceuticals for the treatment of acute hepatic porphyria (AHP). In November 2019, givosiran was approved in the USA for the treatment of adults with AHP based on the positive results from the multinational, phase III ENVISION trial. In the EU, givosiran received a positive opinion in January 2020 for the treatment of AHP in adults and adolescents aged 12 years and older. This article summarizes the milestones in the development of givosiran leading to this first approval for the treatment of adults with AHP.

PubMed Disclaimer

References

    1. Mol Ther Nucleic Acids. 2015 Nov 03;4:e263 - PubMed
    1. Hepatology. 2020 May;71(5):1546-1558 - PubMed
    1. J Inherit Metab Dis. 2013 Sep;36(5):849-57 - PubMed
    1. J Hepatol. 2019 Aug;71(2):422-433 - PubMed
    1. N Engl J Med. 2019 Feb 7;380(6):549-558 - PubMed

MeSH terms

Supplementary concepts

LinkOut - more resources